The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Implications of BRCA1 and BRCA2 mutations on taxane sensitivity in patients (pts) with advanced ovarian cancer.
D. S. P. Tan
No relevant relationships to disclose
T. A. Yap
No relevant relationships to disclose
M. M. Hutka
No relevant relationships to disclose
P. Roxburgh
No relevant relationships to disclose
E. Grzybowska
No relevant relationships to disclose
C. Gourley
No relevant relationships to disclose
M. E. Gore
No relevant relationships to disclose
S. B. Kaye
No relevant relationships to disclose